These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7125606)

  • 1. Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate.
    Wiley RG; Gralla RJ; Casper ES; Kemeny N
    Ann Neurol; 1982 Aug; 12(2):175-83. PubMed ID: 7125606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
    Casper ES; Vale K; Williams LJ; Martin DS; Young CW
    Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
    Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V; Van Oosterom A; Mouridsen HT; Cheix F; Somers R; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):81-4. PubMed ID: 6211362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
    Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
    Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
    Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overproduction of the first three enzymes of pyrimidine nucleotide biosynthesis in Drosophila cells resistant to N-phosphonacetyl-L-aspartate.
    Laval M; Azou Y; Giorgi D; Rosset R
    Exp Cell Res; 1986 Apr; 163(2):381-95. PubMed ID: 2869965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool.
    Katsafanas GC; Grem JL; Blough HA; Moss B
    Virology; 1997 Sep; 236(1):177-87. PubMed ID: 9299630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
    Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.